Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can ...

ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trials Roflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile ...

Please provide your email address to receive an email when new articles are posted on . AB-101a improved mild to moderate atopic dermatitis in pediatric patients as young as 2 years old. All primary ...

—In a small study, patients with mild atopic dermatitis were recruited to wear an artificial intelligence (AI)-enabled, hand-mounted sensor that triggers feedback designed to decrease nocturnal ...

A wearable sensor that sticks onto the back of the hand and uses an artificial intelligence (AI) algorithm to monitor scratching activity when the wearer sleeps has been shown to reduce subconscious ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults and children previously treated with Vtama cream ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an AI-trained wearable sensor with vibrating feedback, the device significantly ...

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing ...

WESTLAKE VILLAGE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

In fully adjusted models, kids with atopic dermatitis had a 44% increased risk of IBD (HR 1.44, 95% CI 1.31-1.58), while adults had a 34% increased risk (HR 1.34, 95% CI 1.27-1.40) compared with ...

BRIDGEWATER, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and ...